NCT05190445 2022-09-08Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ AndenocarinomaPieris Pharmaceuticals, Inc.Phase 2 Active not recruiting80 enrolled